A Phase I study to evaluate the safety and dosimetry of 68Ga-OncoACP3 in patients with prostate cancer
PH-ACP3GA-01/24
Phase 1 other active
Quick answer
A Phase I study to evaluate the safety and dosimetry of 68Ga-OncoACP3 in patients with prostate cancer for Patients with prostate cancer with: -suspected metastasis who are candidates for initial definitive therapy -suspected recurrence based on elevated serum prostate-specific antigen (PSA) level (i.e., a progressive and confirmed serum PSA level > 0.2 ng/mL) -metastatic disease who might be candidates for treatment with 177Lu-labelled PSMA ligands is a Phase 1 program (other) at Philogen S.p.A. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Philogen S.p.A.
- Indication
- Patients with prostate cancer with: -suspected metastasis who are candidates for initial definitive therapy -suspected recurrence based on elevated serum prostate-specific antigen (PSA) level (i.e., a progressive and confirmed serum PSA level > 0.2 ng/mL) -metastatic disease who might be candidates for treatment with 177Lu-labelled PSMA ligands
- Phase
- Phase 1
- Modality
- other
- Status
- active